Europe Lyophilized Injectable Market

The Europe lyophilized injectable market is expected to grow from US$ 808.34 million in 2022 to US$ 1,108.45 million by 2028. It is estimated to grow at a CAGR of 5.4% from 2022 to 2028.     

Increasing Demand for Contract Research Manufacturing Services

Freeze drying, or lyophilization, is a drying process that consists of the sublimation of ice crystals into vapor. Lyophilization is a process based on negative temperatures and the product's activity and stability. Moreover, in this process, active ingredients are better retained while limiting any damage to the product and avoiding any degradation of the molecules. Thus, freeze-drying is especially popular in pharmaceutical and diagnostic sectors. The increased quality and extended shelf life of lyophilized injectable drugs are creating opportunities to implement the lyophilization process in product manufacturing. Contract manufacturing and research services are in huge demand, delivering lyophilized injectable drugs to offer high-quality products to end users. Moreover, many pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which is growing the demand for contract research and manufacturing services (CRAMs) for manufacturing. Furthermore, CRAMs play crucial roles in providing additional capacities to mitigate the risk of supply shortages by offering additional sites for pharmaceutical companies with multisite supply strategies and backup capacities. Furthermore, safe transit, extended pharmaceutical storage life, and many other advantages offered by lyophilized injectables are increasing the adoption of the lyophilization technique by many enterprises across the region.

Market Overview

The Europe lyophilized injectable market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. Germany has a well-developed healthcare system. All legal & German residents are entitled to free necessary medical help, funded by a statutory contribution system. All residents must have medical insurance covering outpatient, inpatient, medical health, and prescription drug. Respiratory disease is one of the most common causes of death in Germany, which includes lung disorders and cancer. Moreover, changing lifestyles among the young population led to an increase in metabolic and autoimmune disorders, fueling the demand for lyophilized injectables. Respiratory disorders are one of the common causes of death along with lung cancer which are further supported by the increase in cardiovascular disorders which accounts for approximately 40% of deaths in Germany. According to the WHO 2020 report, Lung cancer is the third leading cause of death among the German population, with a prevalence rate of 10.3% of the total cancer cases. On the other hand, due to developed healthcare facilities and a rise in the prevalence of infectious diseases, Germany has a broad spectrum of antibiotics, leading to the increased use of antibiotics daily, creating the demand for lyophilized injectables. Moreover, high cost of transportation, increase in carbon footprints, and long shelf life have increased the demand for lyophilized drugs in the country. 

Europe Lyophilized Injectable Market Revenue and Forecast to 2028 (US$ Million)

Europe Lyophilized Injectable Strategic Insights

Strategic insights for the Europe Lyophilized Injectable provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Lyophilized Injectable Report Scope

Europe Lyophilized Injectable Regional Insights

The geographic scope of the Europe Lyophilized Injectable refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Lyophilized Injectable Market Segmentation    

The Europe lyophilized injectable market is segmented based on type of packaging, type of delivery, indication, end user, and country.

• Based on type of packaging, the Europe lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held the largest market share in 2022.

In terms of type of delivery, the Europe lyophilized injectable market is categorized into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held the largest market share in 2022.

• Based on indication, the Europe lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held the largest market share in 2022.
• Based on end user, the Europe lyophilized injectable market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held the largest market share in 2022.
• Based on country, the Europe lyophilized injectable market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022.    
• Aristopharma Ltd.; Baxter; CordenPharma International; Credence MedSystems, Inc.; Curia Global, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma are among the leading companies operating in the Europe lyophilized injectable market.